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Abstract
The concept that the growth hormone (GH) is a merely metabolic pituitary hormone 
with effects on the longitudinal growth of the organism until the end of puberty has been 
questioned in recent years. We know today that the expression of GH also occurs in vir-
tually all organs and tissues where it performs very important autocrine/paracrine and 
even intracrine functions. GH acts on all organs and tissues, being particularly important 
in the development of the brain during the fetal period. In addition, the hormone, after 
interacting with its membrane receptor, is internalized together with its receptor, allow-
ing it to reach the cell nucleus where it acts as a transcription factor. In the first part of this 
review, we will analyze the effects of GH on the brain, the cardiovascular system, and the 
gonadal system, as well as the adverse effects that occur in the GH deficiency not treated 
in children and adults. GH is absolutely necessary for a normal brain development and 
also for repairing the nervous system after an injury. Moreover, GH plays a very impor-
tant role in the cardiovascular system, as well as in normal gonadal functioning.
Keywords: GH deficiency, IGF-I, GH and nervous system, GH and cardiovascular 
system, GH and gonadal functioning
1. Introduction
Almost a century ago it was reported that the treatment of rats with bovine anterior pituitary 
gland extracts led to an increase in the growth of the animals treated with these extracts [1]; 
however, it was not until 35 years later, when from these pituitary extracts, from humans, in 
this case, the factor responsible for this effect on growth could be isolated and administered to 
human dwarfs that then began to grow normally [2], but this growth factor had to be obtained 
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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from human cadavers, and it was not pure and safe for its therapeutic use, until in 1971 its 
primary sequence was characterized and became known as growth hormone (GH). After that, 
and due to the development of genetic engineering, it was possible to start producing, since 
1981, using recombinant DNA technology, unlimited amounts of the pure and safe hormone, 
obtained both from prokaryotes and eukaryotes, to be used in the treatment of children with 
GH deficiency (GHD).
Soon, the clinical use of GH and preclinical investigations allowed to know that the hormone 
was not only responsible for the longitudinal growth of the organism, but also it is a metabolic 
hormone with a counterregulatory function (it produces hyperglycemia since it antagonizes 
the actions of insulin on tissue uptake of glucose and induces lipolysis and protein anabo-
lism). Moreover, GH induces the expression of many different growth factors (such as insulin-
like growth factor I [IGF-I]) and exerts direct effects on cellular proliferation, differentiation, 
and survival [3].
In the last years, several investigations modified this classical description of GH as the hor-
mone responsible for growth. While there are no doubts about the fact that GHD children 
grow defectively until they are treated with GH, many data indicate that the GH-growing 
effect mainly depends on the GH-induced liver production of IGF-I. In turn, the liver pro-
duction of IGF-I is conditioned by the nutritional status of the organism, particularly the 
hepatic metabolism of glucose, and IGF-I is the hormone responsible for the longitudinal 
growth of the organism, a fact clearly seen in children of short stature in whom a defect 
in the hepatic receptor for GH (GHR) impedes that GH induces hepatic IGF-I expression 
[4, 5]. In this situation there are high levels of plasma GH but extremely low levels of 
plasma IGF-I, a condition that also can be seen GHR null mice [6, 7]. The administration 
of recombinant IGF-I reverts this growth problem, as it happens in children with Laron 
syndrome. Moreover, growth velocity in obese children is normal, despite that obesity leads 
to decreased or practically absent GH secretion, but in them, plasma IGF-I level is high [8, 
9]. On the contrary, undernourished children or anorexia nervosa patients present high GH 
secretion but extremely reduced plasma IGF-I levels leading to decreased growth velocity 
[10, 11]. Curiously, there have been reported cases in which growth is normal and the final 
height is even above the target height in patients with persistent untreated GHD and unde-
tectable IGF-I levels [12]; these patients suffered combined pituitary hormone deficiencies 
after resection of craniopharyngiomas and hypothalamic tumors. This led the authors to 
suggest that growth factors different to GH, IGF-I, insulin, or prolactin could play a growth-
promoting role [12].
Currently, there are some other important concepts that go further to the classical descrip-
tion of GH. For instance, we know that there is a peripheral expression of the hormone, in 
practically all the tissues and organs where it plays an autocrine/paracrine role in the cells [3]. 
Therefore, besides the pituitary GH, there is a peripheral GH system owning specific proper-
ties. On the other side, the hormone, after interacting with its GHR in the cell membrane, is 
internalized together with its receptor via the endosomal pathway [13–15]. Once inside the 
cell, the hormone, which has arrived from the plasma, and its GHR are translocated to the 
nucleus where they act as transcription factors [13]. Therefore, the detection of the GHR in a 
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cell nucleus indicates that there has been a previous interaction between GH and its receptor 
at the level of the membrane of this cell. This concept is schematized in Figure 1.
Data from our group indicate, at least in rats, that once internalized, GH can undergo a tissue-
specific proteolytic processing, which originates different molecular forms. The actions of 
these GH-derived forms are unknown, but the type of them depends on the sex and age of 
the animal [16].
A review of the multiple actions that GH performs in the organism, far beyond its classically 
defined effects, can be seen in [3, 17].
Of course, any child with GH deficiency should receive hormone replacement therapy, but 
this does not always happen, and in the case of adults whether or not they are GHD, GH 
secretion decreases gradually with age, after age 20 [18], which may have a causal relation-
ship with cardiovascular events and neurodegenerative diseases typical of aging.
Figure 1. GH induces the translocation of its receptor to the nucleus of the cell. (1) After the binding of extracellular GH 
to its membrane receptor, a number of signaling pathways are activated (2) producing different biological effects. (3) GH 
and its receptor also are internalized via endosomes. There they suffer proteolytic degradations giving origin to shorter 
molecular forms which perhaps have a biological significance. (4) The internalization of GH and its receptor allows that 
they are translocated to the nucleus of the cell, where they act as transcription factors.
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In this review we will analyze the possible harmful effects that the lack of GH can produce on 
a series of tissues and organs in the human body, without considering the known affectation 
of the longitudinal growth that occurs before puberty ends in untreated GHD children.
2. Untreated GH deficiency
Since many years ago, to establish that there is GHD implies the analysis of the amplitude of 
the GH response to at least two provocative stimuli, such as insulin-induced hypoglycemia, 
oral clonidine administration, propranolol plus exercise, etc. However, in many cases these 
tests produce a number of false-positive or false-negative responses [19]. This is due to the 
existence of an intrinsic hypothalamic-somatotroph rhythm, as we demonstrated in 1989 [20], 
that can condition the GH response to a provocative stimulus. As far as we know, the unique 
test in which no errors occur is the clonidine-GHRH test [21], but GHRH is no longer available 
in Spain and many other countries. The consequence of the lack of provocative tests that do 
not give uncertain results is that many children do not receive GH replacement therapy when 
in fact they need it.
2.1. GHD and nervous system functioning
Both GH and IGF-I play key roles in the development, maturation, and function of the brain 
[22, 23]. In fact, the presence of GHR in the brain is detected very early during neural develop-
ment [24]. This implies that GH has to be present in the brain for interacting with its receptor 
[24]. This cerebral GH can come from the fetal anterior pituitary gland since the presence of 
this hormone in this gland has been identified toward week 7 postconception, and in plasma 
it is already detectable by 10 weeks of pregnancy [25, 26]. However, although it is well known 
that plasma GH can easily reach the central nervous system (CNS) [24], since GH-binding 
sites exist in the choroid plexus where they may act as carriers for plasma GH, a number of 
data indicate that the own GH is also synthesized in the CNS [27, 28], where, curiously, its 
regulation seems to be different to that of the pituitary GH. IGF-I is also synthesized in the 
CNS [29], and its expression, induced by GH, has been detected in neural stem cells from 
fetal human forebrains [30]. Both GH and IGF-I play a very important reparative role after a 
brain injury, a hypothesis postulated a long time ago [31] and later proved by many preclini-
cal and clinical studies, regardless of whether the experimental animals or human patients 
were GHD or not [32–49].
Of interest here and before analyzing the effects of the lack of GH on the functioning of the 
brain is the case of children born small for gestational age (SGA) because of intrauterine 
growth retardation (IUGR) [50]. Together with several affectations that may occur later in their 
life (increased cardiovascular risk, diabetes mellitus type 2, and renal diseases), these children 
usually show decreased intelligence and cognition [51], especially manifested by the decrease 
of short-term memory. Animal studies in which IUGR had been induced showed that there 
was a decreased volume of both hippocampus and cerebellum [52, 53], a delayed neuronal 
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migration to the cortex [54], and delayed dendritic and axonal outgrowth [53, 55, 56]; in addi-
tion, there was cortical thickness, decreased number of neurons [52, 53, 57, 58], and clearly 
reduced myelination [53, 55, 59, 60]. Similar results have been found in premature children 
with IUGR in whom there is a reduction of total brain volume, mainly in cerebral cortical 
gray matter [61–63], later traduced in attentional deficit, among other cerebral deficits, such as 
visual affectations. These concepts are schematized in Figure 2.
While it is now clear that the system GH/IGF-I plays a key role in the development of the 
fetal brain, although the pituitary GH does not exert any effect on the longitudinal growth of 
the fetus [3], there are no data indicating that IUGR children suffer from a deficient or absent 
GH production by the neural stem cells during the fetal development. It is also not known 
how the regulation of the cerebral production of this hormone takes place, but in any case 
and based on the data presented, it is reasonable to think that in these children with IUGR, 
a treatment with GH should be administered shortly after birth, to avoid and/or reduce the 
described deficits, something that generally does not occur. If a child with short stature is 
treated with GH, to increase his height, treatment usually does not begin before 4–5 years of 
age, but at these ages, the brain has already developed.
Similar brain deficiencies, although perhaps more marked, occur in untreated GHD children. 
Lack of attention and perception, deficient executive functions, and poor short-term mem-
ory are usual cognitive impairments observed in these children, who also show behavioral 
disorders. The same happens in GHD adults, in whom, in addition, there is a deteriorated 
psychological well-being. These impairments in cognitive functioning, especially subnormal 
memory speed, have been visualized by functional magnetic resonance imaging [64]. GH 
Figure 2. Schematic description of the affectations that may happen in children with IUGR or prematurity plus 
IUGR. Red arrow indicates the main alterations that may appear in these children.
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replacement therapy recovers these deficits, both in children and adults, leading to marked 
improvements in the quality of life [65–71].
The question that should be asked now would be: how does GH exert these important actions 
in cognitive functions?
GH seems to be a very important regulator of hippocampus-dependent spatial learning and 
memory, therefore being able to revert memory deficiencies produced by alterations in cho-
linergic neurons and an imbalance in hippocampal glutamatergic and GABAergic synapses 
[72]; in addition, GH increases the blood flow to the brain and induces, via activation of PI3K/
Akt pathways, the translocation of Glut4 vesicles to the plasma membrane for allowing the 
entry of glucose in neurons [73], and enhancement of excitatory synaptic transmission through 
NMDA receptors [74–77]. Although these studies have been carried out in rats, our recent 
data in an older woman support these effects of GH, not only in the hippocampus but also in 
practically all cortical areas, as measured by PET scans performed before GH administration 
and 1 month later [49]. It is likely that these effects of GH on cognition and the metabolic activ-
ity of the brain are also due to the effects of the hormone on the adult neurogenesis, both in 
physiological conditions and after a brain injury. It is also possible that, apart from the direct 
effects of GH in the brain, some of its actions are mediated by the induction of the expres-
sion of several neurotrophic factors, such as IGF-I, brain-derived neurotrophic factor (BDNF), 
erythropoietin (EPO), vascular endothelial growth factor (VEGF), epidermal growth factor 
(EGF), and some cytokines [3]. GH also modifies the levels of the main neurotransmitters 
(serotonin, noradrenaline, dopamine, the glutamatergic system, the opioid system, and the 
cholinergic system) in several brain areas, although the type of modification differs according 
to the brain area (for review, see [3]).
As stated above, the pituitary secretion of GH decreases progressively throughout aging; con-
sequently, human adults suffer affectations in their cognitive functions, mainly short-term 
memory and their quality of life. Therefore, older people suffer a kind of GHD which can be 
reversed with GH replacement therapy.
There are other pathological situations in which a non-classic GHD appears, susceptible of 
being corrected, total or partially, with GH administration. This is the case, for instance, of 
children with cerebral palsy, traumatic brain injuries, stroke, spinal cord injuries above T5–
T6, or neurosensorial hearing loss, and even injuries in central or peripheral nerves.
Data from our group indicate that in a large number of children with cerebral palsy, 70% of 
them lacked normal GH secretion [78]. We do not know if this GHD is a consequence of the neo-
natal injury or if it occurs as a result of the high spasticity that leads to a deficient production of 
IGF-I, but in any case GH administration in these children is very useful and helps to the kine-
sitherapy and the recovery of lost brain functions [40, 79]. Similar recoveries, after GH admin-
istration and rehabilitation, have been seen in traumatic brain injuries [35–37, 39, 41–44, 47] 
and after a stroke, both in rats [48] and humans [80, 81]. Figure 3 shows the recovery of a 
52-year-old man who, 1 year previously, had suffered an ischemic infarction of the left middle 
cerebral artery, which led to aphasia and right hemiplegia. We treated him with GH and 
rehabilitation, and 18 months later he had fully recovered, without any sequel.
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In the case of the spinal cord, injuries above T5–T6, there is a loss of the afferent inputs 
from the spinal cord to the sympathetic ganglionic chain resulting in a decreased or absent 
supply of catecholamines to the hypothalamus. The result of this situation would be an 
increased hypothalamic somatostatin release and, consequently, deficient or insufficient 
GH secretion [82]. This GHD in patients with spinal cord injuries had been reported years 
ago [83, 84], but never were they treated with GH, until 2007, when we began to treat these 
patients with the hormone and rehabilitation, based on the fact that there are neural stem 
cells in the spinal cord ependyma whose proliferation and differentiation is stimulated by 
GH, with good or very good results in many cases (Figure 4), although we still have not 
published our results.
Recently, the administration of GH to this type of patients has been reported to be safe and 
effective [85]. The effects of GH on the spinal cord have been clearly demonstrated by our 
group in a young child affected by caudal regression syndrome at the L2 level [86]. The treat-
ment started when the patient was 3 months old. Five years later and, even though the patient 
Figure 3. Recovery from an ischemic stroke. The patent suffered aphasia and right hemiplegia. He was treated with 
rehabilitation and GH (0.6 mg/day during 3 months, followed by 1 month without GH administration, and again 
another 3 months under GH treatment. This pattern was conducted over 18 months). At discharge he had recovered all 
lost functions. In the picture, it can be seen how the patient moves perfectly the right arm and leg, previously paralyzed.
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also suffered from a lack of sacral bone, he was able to walk with the help of a cane and to get 
up from the ground without help, has full sensitivity in the legs and feet, and has sphincter 
control. This indicates that, although the spinal column did not grow, new spinal roots were 
formed that fully innervated the legs, feet, and sphincters. These effects, the first case in the 
world, only can be attributed to GH.
Neurosensorial hearing loss is a quite common finding in children with perinatal prob-
lems and also in children with alterations in GH secretion or its signaling pathways [87, 
88]. We treated with GH and specific auditory stimulation a child with cerebral palsy, 
Figure 4. Recovery from a complete spinal cord injury (level C5–C6, ASIA A). The injury occurred 6 years before, at 
16 years old. (1) The patient at admission. He could only move his arms but did not reach the mouth. He had a great 
spasticity. He was treated with rehabilitation and GH (1 mg/day, following the same pattern described in Figure 3). (2) 
Two years later he was able to walk with the help of a walker. Currently, 10 years after discharge, he walks 5 km/day, 
although he still needs the walker.
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beginning when he was 3.5 months old, and 14-months later he was fully normal [89]. 
Most likely hearing loss was recovered due to the effect of GH on the production of hair 
cells from stem cells existing in the cochlear sensory epithelium. These stem cells are pres-
ent only in very young children and respond to GH proliferating and differentiating. This 
was the first known case in which hearing loss was recovered by the administration of this 
hormone.
GH is also a promising therapy for central and peripheral nerve injuries. For instance, a com-
mon finding in children with cerebral palsy is a delayed conduction from the retina to the 
occipital cortex, but we corrected it with the administration of GH and visual stimulation with 
a tachistoscope [90] (Figure 5).
In this case, it is likely that the hormone increased the number of fibers in the optical nerve 
and promoted myelination of them. A similar regeneration was obtained in an untreated GHD 
patient, 15 years after she suffered a brain surgery because of a bulbar astrocytoma (what 
was the cause of the GHD). The surgery produced paralysis of oropharyngeal structures, 
paralysis of vocal cords, and lack of primary esophageal peristalsis, because of iatrogenic 
Figure 5. Evoked visual potentials (EVP) in 36 young children with cerebral palsy. Note the significant decrease in the 
conduction velocity from the retina to the occipital cortex, after being treated with GH (0.04 mg/kg/day) and visual 
stimulation with a tachistoscope. This indicates an increase in the number of fibers and myelination of the optical nerve.
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palsy of cranial nerve pairs IX, X, and XII. Therefore, the patient was unable to speak or 
swallow, her tongue was atrophic, and vocal cords were paralyzed. Moreover, her mouth was 
continuously full of sympathetic highly dense mucous saliva, and there was the need of noc-
turnal volumetric ventilation because of the severity and frequency of her sleep apneas. Eight 
months after beginning a treatment with GH and speech therapy, the patient was discharged 
practically recovered [91] (Figure 6).
Since the patient had undergone an intense oral rehabilitation for almost 15 years, without 
any success, it seems clear that the administration of GH was the factor responsible for the 
recovery of damaged cranial nerves.
We also demonstrated, in rats, that the administration of GH administration led to complete 
functional recovery of the sciatic nerves after their transection [92], promoting the appearance 
of a high number of axons and Schwann cells, while in the group of rats treated with placebo, 
a persistent paralysis of the affected limb was present.
Figure 6. Recovery from cranial nerve pair damage 15 years after bulbar surgery. (1) The patient at admission was 
unable to move the tongue, it was atrophic, and the mouth continuously accumulated highly dense mucous saliva 
(sympathetic saliva). (2) Four months after being treated with GH (1 mg/day, 5 days/week) and speech therapy, the 
tongue had increased its size and showed important mobility; the patient began to speak and ceased to accumulate 
sympathetic saliva. (3) Indicates the inability to move the tongue forward (red rectangle). (4) Four months later these 
forward movements clearly improved (red rectangle). (5) At admission there was paralysis of the vocal cords. (6) Eight 
months later the vocal cords move normally. The patient was discharged practically recovered from her dysfunctions.
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In summary, from these and many other data, it is clear that GH is a hormone that plays many 
important roles in the development and functional maintenance of the nervous system, cen-
tral and peripheral, and/or its repair when an injury exists. These effects have nothing to do 
with the longitudinal growth of the organism, but do not appear in untreated GHD children 
or adults when really they do need the replacement therapy with the hormone.
2.2. GHD and cardiovascular system
As it happens in the brain during fetal development, GH has direct effects in the heart of 
the fetus; the hormone induces myocardial growth and improves the cardiac function [93]. 
Fetal GH induces mRNA expression of specific contractile proteins, increases the force of 
cardiac contraction, and induces the phenoconversion of myosin toward the low ATPase 
activity V3 isoform [93]. This allows to increase the number of actin-myosin cross-bridges 
and their attachment time, enhances protein calcium sensitivity and calcium availability, 
and allows the myocardium to function at lower energy cost. Therefore, the fetal heart is 
able to beat at high frequency without spending too much energy. After birth, this changes, 
and myocardial remodeling occurs; the V1 myosin is then expressed, which implies a 
higher ATPase activity. Some of these effects of GH on the fetal heart may be produced by 
GH-induced IGF-I expression in the heart. The GH-IGF-I axis may also regulate cardiac 
metabolism, by increasing amino acid uptake, protein synthesis, cardiomyocyte size, and 
myocardial-specific gene expression. In addition, GH-induced IGF-I reduces apoptosis of 
cardiomyocytes, thus preventing myocyte loss, and increases the collagen deposition rate 
in the heart [94–99].
Although many of the aforementioned studies come from preclinical research, the important 
role that GH plays at the myocardial level can be easily observed by analyzing what happens 
in untreated GHD children and adults. In them, there is cardiac atrophy with a significant 
reduction in the left ventricle mass, relative wall thickness, and cavity dimensions, in com-
parison with age-, sex-, and height-matched controls [100–104]. These patients also have a low 
ejection fraction, low cardiac output, and high peripheral vascular resistance [100, 102–105]. 
As is logical, physical exercise increases these alterations; consequently, the intensity of exer-
cise and its duration are reduced in both GHD children and adults [106, 107]. However, adult-
onset GHD does not produce a reduction in cardiac mass. GH replacement therapy in GHD 
adults exerts significant positive effects on cardiac abnormalities, as it has been shown in 
several trials. The left ventricular mass increases, cardiac performance improves, and diastolic 
filling and systolic function also improve, both in GHD children and adults when they receive 
a GH treatment [100–102, 104, 105, 108] (Figure 7).
Therefore, and given the positive effects of GH on the heart, it is likely that GH treatment 
may be useful in patients with heart failure, even if they are not GHD. Many recent studies 
support such a possibility, and the treatment with GH has been proposed and carried out 
with very good results in untreated GHD children and adults with heart failure and also 
in patients suffering this affectation even though they are not GHD [109–117], although 
there are studies suggesting that this GH therapy only provides positive results in GHD 
patients [118].
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In any case, the interactions between the heart and GH are very complex. An example of it is 
the fact that the heart may condition body growth in children with heart diseases. This is due 
to the fact that, in these situations, cardiomyocytes produce and release a peptide known as 
GDF15, which inhibits liver signaling by GH; therefore, liver IGF-I is not released, and body 
growth is affected [119].
The GH/IGF-I system also exerts important actions at the vascular level. For instance, this 
system activates the production of nitric oxide (NO) that induces the relaxation of arterial 
smooth muscle cells; as a consequence, the vascular tone is reduced. In addition, NO inhib-
its the proliferation and migration of smooth muscle cells, decreases platelet adhesion, 
and decreases lipoxygenase activity and oxidized LDL cholesterol [120–124]. These are 
some of the reasons by which GHD patients show an abnormal vascular reactivity [125], 
although the lack of effect of GH on the expression of the vascular smooth muscle KATP 
channel may also be involved in this affected vascular tone observed in untreated GHD 
patients [126]. GHD have an increased risk of atherosclerosis and vascular mortality [127]. 
GH treatment restores the vascular resistance and vasodilation and even may reverse early 
atherosclerosis.
GHD patients present markedly increased muscle sympathetic nerve activity [128], which 
seems to be of central origin and perhaps is an important mechanism leading to secondary 
hypertension and increased cardiovascular morbidity in these patients. In fact, 1 year of treat-
ment with GH induces, in adults GHD, an effect on decreasing sympathetic nerve activity in 
the muscular vascular bed [129].
GH also plays a significant role on angiogenesis, contributing to regulate vascular growth 
and function (for review, see [17]). Most likely this is the reason by which the skin of adult 
GHD patients shows reduced capillary density and permeability, and these are improved 
Figure 7. The effect of GH treatment on cardiovascular functioning in GHD patients. Untreated GHD patients suffer 
several important affectations in the heart. This leads to an increased cardiovascular risk and decreased exercise. GH 
administration reverts (blue arrow) these cardiac affectations and improves the quality of life in these GHD patients.
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after treatment with GH [130]. Retinal vascularization is reduced in children and adults GHD 
[131, 132], although this may be a consequence of decreased IGF-I [132], since the vascular 
effects of GH may be exerted by other angiogenic agents induced by the hormone [17].
In summary, GH plays a very important role in the cardiovascular system, and untreated 
GHD patients suffer the consequences of the lack of the hormone and its mediators [109, 
133, 134] and the risk of developing atherosclerosis, and suffering from cardiac affectations 
increases in them.
2.3. GHD and gonadal functioning
2.3.1. GHD and testicular functioning
In males, the effects of GH on testis seem to be different according to the species and the age 
of the individual. This is the case of rats and mice. Dwarf rats have small testis and normal 
spermatogenic function, suggesting that GH does not play a role in spermatogenesis during 
puberty and adult life, although the small testicular size may indicate that these animals have 
a small number of Sertoli cells, which in turn would indicate that GH may be important 
for the development of prepubertal testis [135]. However, homozygous GH-deficient mouse 
mutants (Snell dwarf mice) present infantile seminal vesicles, and spermatogenesis appears 
later in life [135]. From this study, the authors concluded that GHD only partially affects the 
reproductive axis, and this affectation occurs at an early age.
Unlike what happens in the CNS, plasma GH cannot easily access testicular cells within 
the blood-testis barrier. GH gene expression has been detected within the rat, human, and 
chicken testes [136, 137]. GHR has been detected in the human testis, mainly in Leydig cells 
[138]. Factors which regulate GH secretion are similarly expressed in the testis. This is the 
case of growth hormone releasing hormone (GHRH) found in the testis of rats, chicken, and 
humans [136, 137]. This testicular GHRH is capable of stimulating the pituitary release of GH, 
which indicates that it is similar or the same than the hypothalamic GHRH, but it is also able 
to induce the activity of adenylate cyclase (AC) in Sertoli cells [136]. At the testicular level, 
receptors for GHRH have been found in Leydig cells, Sertoli cells, germ cells, and even in 
the prostate, suggesting that this GHRH can exert specific actions on the testicle, different 
from those of GH itself [139]. Another inducer of pituitary secretion of GH, such as ghre-
lin, has also been found in mature Leydig cells of rat and human testis, where it has been 
shown that acting on its GHS-R type 1a receptor modulates the proliferation of Leydig cells 
and the expression of important testicular genes, such as the stem cell coding factor [140]. 
Interestingly, negative regulators of GH secretion and the actions of this hormone, such as 
somatostatin (SS) and its receptors (SSTR1–SSTR5), have been detected in Sertoli cells of mice 
[141]; treatment with somatostatin significantly promotes the apoptosis of these cells and 
decreases the expression of IGF-I together with a dose-dependent suppression of the mRNA 
level of the kitl gene, which is important in the regulation of spermatogenesis. These findings 
suggest that somatostatin and its receptors (mainly SSTR2 and SSTR5) play an important role 
in the regulation and development of Sertoli cells [141]. All these data indicate that practically 
all the components of the hypothalamus-somatotroph axis exist in the testicle, although it is 
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unknown exactly how they act and if there is any relationship with the similar endocrine axis. 
These concepts are shown in Figure 8.
Despite the fact that, in this regard, the testis seem to behave like a small hypothalamic-
pituitary gland, endocrine GH promotes testicular growth and development and stimulates 
gametogenesis and steroidogenesis in the adult testis. These actions seem to be mediated by 
IGF-I, since it can recover testicular differentiation in fetal mice treated with GH antibodies 
and testicular growth in children with Laron syndrome [142, 143].
In vitro, GH is a potent steroidogenic factor that stimulates androgen and estradiol produc-
tion by Leydig cells in a number of species including humans. In vivo, GH treatment has 
been seen to increase the production of testosterone, induced by chorionic gonadotropin, 
and seminal plasma volume, in fertile GHD human patients [144, 145]. Similar effects have 
been described in boys with GHD after being treated with GH [146]. However, and con-
trarily to what should be expected, GH treatment in hypopituitary or moderately obese 
Figure 8. Hormonal factors involved in the functioning of testicular Leydig and Sertoli cells. Left: In Leydig cells there is 
expression of a number of hormones related to GH. There is GHR in the nucleus of these cells, indicating that there is GH 
expression in Leydig cells (GH?), although the nuclear GHR could proceed from the interaction of endocrine GH with 
its membrane receptor. This interaction leads to the expression of IGF-I inside the Leydig cell, and it is also responsible 
for the production of testosterone (induced by LH), which is secreted to the plasma. Interestingly, there are receptors 
for GHRH in the membrane of Leydig cells, although its role is unknown. In addition, another important inducer of 
GH secretion, such as ghrelin, has been found to be expressed in Leydig cells. Ghrelin acts (blue arrow) on its receptor 
GHS-R1a inducing the proliferation of Leydig cells and increasing the activation of stem cell coding factor. Right: As in 
Leydig cells there are GHR in the membrane of Sertoli cells; this may explain the presence of the GHR in the nucleus 
of these cells, although it is not well known, as it is not known if GH is expressed in Sertoli cells (GH?). In Sertoli cells 
there are receptors for GHRH (GHRH-R) which activate adenylate cyclase, although the effects produced are not known. 
Curiously, somatostatin (SS) and its receptors (mainly SSTR2 and SSTR5) are expressed in Sertoli cells. The interaction 
of SS with its receptors (blue arrow) leads to the inhibition of IGF-I and kitl gene expression (red arrows) and induces 
apoptosis of these Sertoli cells.
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men decreases the concentrations of total serum testosterone [147, 148]; most likely this 
effect is due to an increased aromatase activity and the resulting increased conversion of 
testosterone to estradiol [149]. In this study it was also found that high GH plasma levels 
were associated with reduced activity of the anti-Müllerian hormone (AMH), a marker of 
the Sertoli cells.
At this point it would be of interest to analyze if there is GH expression in the testis of 
GHD patients (children or adults) or experimental animals, both in cases of GHD due 
to a traumatic brain injury and a GH gene mutation or deletion, since it has been shown 
that in males born small for gestational age GH treatment does not affect the testicular 
production of inhibin and AMH [150]. That is, it seems that the pituitary GH does not 
play a key role in the testicular functioning, but acts as a co-gonadotropin that improves 
the secretion of gonadotropins (Gns), particularly LH, by acting directly or through IGF-I 
in the activation of GnRH pulse generator by means of the stimulation of hypothalamic 
kisspeptin [151].
It is also important to reflect that the GH variant GHV, seems to be the most abundant GH 
mRNA isoform in the human testis [152], while in chicken the GH 17 kDa variant is predomi-
nant [153].
In summary, from these data, it is likely that, in a normal man, endocrine GH synergizes with 
gonadotropins, potentiating the effects of these hormones on testicular cells, while the role of 
the testicular GH axis and its relationships with endocrine GH remain unknown.
2.3.2. GHD and ovarian functioning
The relationship between GH and ovarian functioning has been widely analyzed since many 
years ago. In humans, and in many other species, GH seems to play a direct role in the 
nuclear maturation of oocytes [154, 155]. In 1990, the existence of a strong immunoreactivity 
for the GH receptor at the nuclear level was described not only in rat oocytes but also in 
practically all the reproductive systems of the rats studied [156]. These data led to suggest 
that GH could play important and direct actions on reproduction. In human oocytes, the 
GHR has been detected in the membrane, in cumulus cells and in the nucleus in mature ova-
ries [157], confirming that GH has to act at this level improving nuclear maturation and the 
expansion of cumulus cells, as has been demonstrated in primates [158], and also improving 
the cytoplasmic maturation of mature oocytes [159]. There is a genetic expression of GHR in 
cumulus cells, mature oocytes, and preimplantation human embryos, in which the expres-
sion of GHR increases from the 4-day morula onwards [154]. This study led to the conclusion 
that, in humans, GH plays a role in the maturation of the oocyte and embryogenesis, from 
its early stages.
Most of the GH effects on the ovarian functioning are exerted by the hormone locally pro-
duced in the ovaries; however, plasma GH released by the pituitary gland or exogenously 
administered also plays an important role in the normal function of the female gonad 
and reproduction [160]. In fact, GH participates in the regulation of puberty and fertility, 
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although these effects may depend on GH-induced changes in Gns secretion, directly or 
via IGF-I [161, 162].
Preclinical and clinical data indicate that an appropriate secretion of GH is needed for sexual 
maturation and maintenance of reproductive functions, while GH deficiency may affect the 
beginning of the puberty and can produce infertility. In humans, the interaction of GH-GHR 
in the ovary promotes the synthesis of sex steroids and induces gametogenesis, inhibits fol-
licular apoptosis, and upregulates ovarian receptors for LH [160, 162, 163]. GHD women, in 
which puberty is delayed and the reproductive function is affected, recover a normal ovar-
ian function when they are treated with GH [163]; the same happens in infertile eugonadal 
women with GH deficiency in whom GH treatment restores fertility and leads to successful 
pregnancies [164].
Although the onset of puberty in girls is a very complex process in which many factors 
participate (genetic, nutritional status, ethnicity, among others), there seems to be a rela-
tionship between increased GH secretion and puberty, since this hormone seems to act as a 
co-gonadotropin that enhances the effects of Gns on the ovarian production of sex steroids 
[165]. In fact, GH deficiency has been identified as the only cause of primary amenorrhea in 
three adolescent women in whom the secretion of gonadotropins was normal, suggesting 
that GH would play a complementary role to gonadotropins for the onset of menarche [166]. 
Therefore, and as stated above, GH deficiency negatively affects ovarian function in humans 
delaying sexual maturation and fertility, a situation that is reversed with GH replacement 
therapy. In addition, GH plays a very important role in ovarian angiogenesis, inducing the 
increased vascularization of one of the primary follicles that begin to maturate during a 
menstrual cycle allowing it to be the dominant follicle which will release the ovule (for 
review, see [167]).
GH also plays a role in the uterus, where the hormone acts very early in gestation. Both 
GH and GHR are expressed in the uterus, independently of the existence or not of preg-
nancy [3]. GH induces uterine hypertrophy facilitating the implantation of the embryo. In 
women with thin endometrium, the administration of GH leads to greater endometrium 
thickness; very early, the hormone leads to higher implantation rates and greater clinical 
pregnancy rates than with untreated patients [168]. These effects are due to the prolifera-
tion of endometrial cells and increased vascularization via induction of the expression of 
VEGF-A. The increased rates of implantation seem to be a consequence of GH-induced 
increased production of metalloproteinases and stimulation of trophoblast cells prolifera-
tion, thus allowing the formation of the blastocyst cavity and invasion of the endometrium, 
as it has been seen in mice [169].
In summary, GH plays very important roles in all stages of the ovarian development and 
functioning, and recent studies indicate that this hormone can be an important factor as adju-
vant therapy for in vitro fertilization and embryo transfer in infertile women or poor ovarian 
responders. Untreated GHD females present delayed (or absent) onset of the puberty, and 
impaired fertility is more marked in female patients with childhood-onset hypopituitarism; 
they have lower fertility rates and less positive pregnancy outcomes [170]. GH replacement 
therapy reverts these alterations.
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3. Conclusions
GH is a key hormone for the normal development of the brain and for repairing the ner-
vous system when it suffers any injury. This hormone also contributes to the repair of the 
cardiovascular system, particularly increasing the blood flow by inducing the formation 
of collateral vessels that allow overcoming a circulatory obstruction and repairing the 
arterial intimate layer damaged by an arteriosclerotic process. In addition, the hormone 
plays an important role at the gonadal level in both sexes, perhaps more important in 
women, facilitating fertility. Untreated GHD patients suffer the consequences of the lack 
of the hormone when any of the organs here described is damaged, as it has been analyzed 
in this review.
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